Categories
Blood Cancer

Preliminary results from NP40126: Glofitamab and R-CHOP in NHL [Video]

Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, comments on the ongoing, Phase I NP40126 trial (NCT03467373) of glofitamab, a CD20xCD3 T-cell-engaging bispecific antibody, with R-CHOP in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) or treatment naïve diffuse large B-cell lymphoma (DLBCL). A promising safety profile was reported, with a toxicity similar to that of R-CHOP monotherapy, and a reduced rate of cytokine release syndrome (CRS) compared with glofitamab monotherapy. Treatment was additionally administered in a timely fashion, important in curing patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Advances in immunotherapy for lymphoma [Video]

Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, provides an overview of current developments in the field of immunotherapy in lymphoma. A lot of progress has been made in monoclonal antibodies, bispecific antibodies, as well as chimeric antigen receptor (CAR) T-cell therapies. Dr Hutchings additionally comments on looking forward to the next generation of immunotherapies, such as anti-CD20 IgM antibodies. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

The role of measuring MRD in CLL [Video]

Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, describes using minimal residual disease (MRD) monitoring in treating chronic lymphocytic leukemia (CLL). Measuring MRD levels can enable accurate assessment of patients responses to treatment and can accordingly adjust treatment levels. MRD monitoring can additionally predict outcomes to chemoimmunotherapy and certain targeted therapies and Dr Niemann emphasizes the need to create MRD-guided regiments as in the Phase II HOVON-141/VISION trial (NCT03226301). This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

GLOW: Assessing ibrutinib plus venetoclax in CLL [Video]

Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, discusses findings in the Phase III GLOW trial (NCT03462719), which assessed first-line ibrutinib plus venetoclax versus chlorambucil with obinutuzumab in patients with chronic lymphocytic leukemia (CLL). Patients receiving ibrutinib and venetoclax reported lower rates of relapse, and Dr Niemann suggests intermediate minimal residual disease (MRD) as an acceptable endpoint for certain patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

GAIA/CLL13: Venetoclax-based time-limited combination therapies in CLL [Video]

Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, gives an overview of the Phase III GAIA trial (NCT02950051), which assessed standard chemoimmunotherapy versus a combination of rituximab, venetoclax, obinutuzumab, and ibrutinib in patients with chronic lymphocytic leukemia (CLL). Patients received either standard chemoimmunotherapy, rituximab with venetoclax, obinutuzumab with venetoclax, or obinutuzumab with ibrutinib and venetoclax. Rituximab or obinutuzumab with venetoclax were associated with higher rates of undetectable minimal residual disease (uMRD), and whilst addition of ibrutinib added further benefit to patients, more adverse events were reported. Further research is required to identify patient subgroups who will benefit from chemoimmunotherapy the most. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

HOVON 141/VISION: MRD guided time-limited treatment in CLL [Video]

Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, presents results from the prospective, randomized Phase II HOVON-141/VISION trial (NCT03226301), which assessed time-limited venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Patients reaching undetectable minimal residual disease (MRD) after venetoclax and ibrutinib either received maintenance ibrutinib or stopped treatment, and all patients who failed to reach MRD status received maintenance ibrutinib. MRD guided time-limited treatment was proven to be beneficial, where the primary endpoint of progression-free survival (PFS) was met. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.